Johnson & Johnson and Novavax announced results from late-stage clinical trials for their respective coronavirus vaccines. J&J found its vaccine to be 66% effective overall (including 72% in the US and 57% in South Africa), while Novavax found its vaccine to be 89% effective overall (including 49% in South Africa). Both companies were recipients of funding through “Operation Warp Speed” last year, and the US government has secured access to 100M doses from each firm.
Extra: J&J’s vaccine notably uses a single dose, compared to previously approved vaccines from Pfizer and Moderna that require two doses.
The New Paper
This story is from the January 29, 2021 edition of The New Paper – a clear, concise daily briefing that makes fact-first news easy to consume. Try it today.